Colorectal Cancer Screening Outreach for Better Adherence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pragmatic, four-arm study targets adults with an established primary care relationship at Cornell Scott Hill Health. It uses a multicomponent messaging intervention to encourage completion of outstanding or abnormal colorectal cancer screening tests. Eligible participants include those with an incomplete colonoscopy or stool-based test and those with abnormal results lacking timely follow-up, with randomization occurring after a 90-365 day window from the initial order. The trial is led by Yale University, conducted at a New Haven, CT health system site, and focuses on real-world adherence rather than specialized laboratory outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Established adult medicine patient at Cornell Scott Hill health (defined as having a CSHH primary care doctor or \>1 adult medicine visits in the last year).
* Incomplete colorectal cancer screening test defined as an outstanding order for colonoscopy or stool-based CRC screening (e.g., fecal immunochemical test (FIT) or FIT-DNA testing), but no evidence of test completion at the time of randomization. Orders must have been placed between 90-365 days prior to randomization.

OR

* Abnormal stool-based test without follow-up, defined as an abnormal stool-based test result (e.g., positive FIT or FIT-DNA) with no completed diagnostic colonoscopy within 90 days of the result. Patients who meet this criterion will be included in a non randomized arm of the study.

Exclusion Criteria:

* Because this is a pragmatic study of a behavioral intervention to improve colorectal cancer screening adherence, any participants who otherwise meet the inclusion criteria will not be excluded.

Where it's running

• Cornell Scott Hill Health
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Ilana Richman, MD — Yale University
• Study coordinator: Ilana Richman, MD
• Email: ilana.richman@yale.edu
• Phone: 203 737 1024

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prehabilitation before high-risk cancer surgery

  This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07638410

• Personal cancer risk testing using genetic, blood, and tumor monitoring

  This project will test whether combining genetic testing, blood-based analyses, and tumor tissue checks can identify personal cancer risk and detect early recurrence in adults with breast, ovarian, colorectal, melanoma, or certain non-small cell lung cancers.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Turin · NCT07469709

• Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease

  This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.

  Recruiting San Raffaele University · Milan, Lombardy and 3 other locations · NCT07450612

• Blood-based delta-HLD methylation test for detecting colorectal cancer

  This will try a blood-based delta-HLD methylation test to see if it can detect colorectal cancer in people scheduled for colonoscopy or colorectal surgery.

  Recruiting Epiliquid Holding, Inc · Mendoza · NCT07148297

• MBRC-201 dose-finding and safety in advanced metastatic solid tumors

  We will test different doses of an antibody-drug conjugate called MBRC-201 in adults whose advanced metastatic cancers (including prostate, breast, colorectal, lung, and pancreatic cancer) have not responded to standard treatments.

  Recruiting at 7 sites Phase 1/2 MBrace Therapeutics · San Francisco, California and 6 other locations · NCT07145255

• Low-dose trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer

  This will try a lower-dose trifluridine/tipiracil plus bevacizumab regimen for people with metastatic colorectal cancer who have progressed after at least two prior treatments.

  Recruiting at 2 sites Phase 2 Ruijin Hospital · Sanming and 1 other locations · NCT07085169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.